Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia

Author:

Kan Winnie L.1ORCID,Dhagat Urmi23ORCID,Kaufmann Kerstin B.4ORCID,Hercus Timothy R.1ORCID,Nero Tracy L.23ORCID,Zeng Andy G.X.45ORCID,Toubia John6ORCID,Barry Emma F.1ORCID,Broughton Sophie E.23ORCID,Gomez Guillermo A.1ORCID,Benard Brooks A.7ORCID,Dottore Mara1ORCID,Cheung Tung Shing Karen S.23ORCID,Boutzen Héléna4ORCID,Samaraweera Saumya E.6ORCID,Simpson Kaylene J.89ORCID,Jin Liqing4ORCID,Goodall Gregory J.610ORCID,Begley C. Glenn11ORCID,Thomas Daniel710ORCID,Ekert Paul G.121314ORCID,Tvorogov Denis1ORCID,D'Andrea Richard J.6ORCID,Dick John E.45ORCID,Parker Michael W.23ORCID,Lopez Angel F.110ORCID

Affiliation:

1. 1Cytokine Receptor Laboratory, Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.

2. 2Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.

3. 3Department of Biochemistry and Pharmacology and the Australian Cancer Research Foundation Facility for Innovative Cancer Drug Discovery, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia.

4. 4Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

5. 5Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

6. 6Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.

7. 7Division of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.

8. 8Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

9. 9The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

10. 10Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia.

11. 11Begley Biotech Consulting, Wallington, Victoria, Australia.

12. 12Translational Tumour Biology Group, Children's Cancer Institute, Lowy Cancer Centre, University of New South Wales, Randwick, New South Wales, Australia.

13. 13Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

14. 14Cancer Research, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia.

Abstract

Abstract Leukemia stem cells (LSC) possess distinct self-renewal and arrested differentiation properties that are responsible for disease emergence, therapy failure, and recurrence in acute myeloid leukemia (AML). Despite AML displaying extensive biological and clinical heterogeneity, LSC with high interleukin-3 receptor (IL3R) levels are a constant yet puzzling feature, as this receptor lacks tyrosine kinase activity. Here, we show that the heterodimeric IL3Rα/βc receptor assembles into hexamers and dodecamers through a unique interface in the 3D structure, where high IL3Rα/βc ratios bias hexamer formation. Importantly, receptor stoichiometry is clinically relevant as it varies across the individual cells in the AML hierarchy, in which high IL3Rα/βc ratios in LSCs drive hexamer-mediated stemness programs and poor patient survival, while low ratios mediate differentiation. Our study establishes a new paradigm in which alternative cytokine receptor stoichiometries differentially regulate cell fate, a signaling mechanism that may be generalizable to other transformed cellular hierarchies and of potential therapeutic significance. Significance: Stemness is a hallmark of many cancers and is largely responsible for disease emergence, progression, and relapse. Our finding that clinically significant stemness programs in AML are directly regulated by different stoichiometries of cytokine receptors represents a hitherto unexplained mechanism underlying cell-fate decisions in cancer stem cell hierarchies. This article is highlighted in the In This Issue feature, p. 1749

Funder

National Health and Medical Research Council

Cancer Council South Australia

Cancer Council Victoria

Cure Cancer Australia Foundation

Australian Cancer Research Foundation

Leukaemia Foundation

Princess Margaret Cancer Foundation

Ontario Institute for Cancer Research

Canadian Institutes of Health Research

International Development Research Centre

Canadian Cancer Society

Terry Fox Research Institute

Canada First Research Excellence Fund

Canada Research Chairs

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3